{'fraction_non_alphanumeric': 0.02167630057803468, 'fraction_numerical': 0.0, 'mean_word_length': 5.861386138613861, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The quest for biomarkers in IBS—where should it lead us?

Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder which represents a major cost to health‐care services. The diagnosis of IBS is currently performed by means of symptom‐based diagnostic criteria, but there has been an ongoing interest in developing biomarkers which could simplify the diagnosis and/or evaluating the effect of treatments. This article reviews the current literature concerning the proposed biomarkers including those of altered gut motility, of visceral hypersensitivity, of abnormal brain mechanisms, of serum, fecal and mucosal inflammation and of increased intestinal permeability.